Do prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab?
Patients with PSMB1 P11A (G allele) and low CD68 expression seemed to have significantly longer PFS and greater clinical benefit with bortezomib-rituximab versus rituximab.
Paclitaxel inhibition of adhesion molecule expression resulted in impaired NK cell binding to target cells, which may have a negative impact on immune surveillance.